Inhibition of Tumoral VISTA to Overcome TKI Resistance Via Downregulation of the AKT/mTOR and JAK2/STAT5 Pathways in Chronic Myeloid Leukemia

Overview

Journal Biomol Ther (Seoul)

Specialty Pharmacology

Date 2024 Aug 6

PMID 39104205

Authors

Kexin Ai

Mu Chen

Zhao Liang

Xiangyang Ding

Yang Gao

Honghao Zhang

Suwan Wu

Yanjie He

Yuhua Li

Affiliations

Soon will be listed here.

Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment landscape for chronic myeloid leukemia (CML). However, TKI resistance poses a significant challenge, leading to treatment failure and disease progression. Resistance mechanisms include both BCR::ABL1-dependent and BCR::ABL1-independent pathways. The mechanisms underlying BCR::ABL1 independence remain incompletely understood, with CML cells potentially activating alternative signaling pathways, including the AKT/mTOR and JAK2/STAT5 pathways, to compensate for the loss of BCR::ABL1 kinase activity. This study explored tumoral VISTA (encoded by VSIR) as a contributing factor to TKI resistance in CML patients and identified elevated tumoral VISTA levels as a marker of resistance and poor survival. Through and analyses, we demonstrated that VSIR knockdown and the application of NSC-622608, a novel VISTA inhibitor, significantly impeded CML cell proliferation and induced apoptosis by attenuating the AKT/ mTOR and JAK2/STAT5 pathways, which are crucial for CML cell survival independent of BCR::ABL1 kinase activity. Moreover, VSIR overexpression promoted TKI resistance in CML cells. Importantly, the synergistic effect of NSC-622608 with TKIs offers a potent therapeutic avenue against both imatinib-sensitive and imatinib-resistant CML cells, including those harboring the challenging T315I mutation. Our findings highlight the role of tumoral VISTA in mediating TKI resistance in CML, suggesting that inhibition of VISTA, particularly in combination with TKIs, is an innovative approach to enhancing treatment outcomes in CML patients, irrespective of BCR::ABL1 mutation status. This study not only identified a new pathway contributing to TKI resistance but also revealed the possibility of targeting tumoral VISTA as a means of overcoming this significant clinical challenge.

References

Im E, Sim D, Lee H, Park J, Park W, Ko S . Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy. Semin Cancer Biol. 2021; 86(Pt 2):1066-1075. DOI: 10.1016/j.semcancer.2021.08.008. View

Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V . Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res. 2017; 24(7):1562-1573. PMC: 5884702. DOI: 10.1158/1078-0432.CCR-17-2542. View

Hong S, Yuan Q, Xia H, Zhu G, Feng Y, Wang Q . Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy. Protein Cell. 2019; 10(11):840-845. PMC: 6834738. DOI: 10.1007/s13238-019-0642-z. View

Marce S, Cortes M, Zamora L, Cabezon M, Grau J, Milla F . A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML). Exp Mol Pathol. 2015; 99(1):16-8. DOI: 10.1016/j.yexmp.2015.04.007. View

Zheng S, Zhang K, Zhang X, Xiao Y, Wang T, Jiang S . Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway. J Med Chem. 2022; 65(18):11900-11912. DOI: 10.1021/acs.jmedchem.2c00803. View

Patel A, OHare T, Deininger M . Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. Hematol Oncol Clin North Am. 2017; 31(4):589-612. PMC: 5505321. DOI: 10.1016/j.hoc.2017.04.007. View

Schaafsma E, Croteau W, ElTanbouly M, Nowak E, Smits N, Deng J . VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance. Cancer Immunol Res. 2022; 11(1):38-55. PMC: 10544831. DOI: 10.1158/2326-6066.CIR-22-0116. View

Irani Y, Kok C, Clarson J, Shanmuganathan N, Branford S, Yeung D . Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia. Blood Adv. 2023; 7(11):2364-2374. PMC: 10220272. DOI: 10.1182/bloodadvances.2022008854. View

Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B . Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022; 15(1):113. PMC: 9389804. DOI: 10.1186/s13045-022-01334-z. View

10.

Xie S, Huang J, Qiao Q, Zang W, Hong S, Tan H . Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol Immunother. 2018; 67(11):1685-1694. PMC: 11028359. DOI: 10.1007/s00262-018-2227-8. View

11.

Eide C, OHare T . Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. Curr Hematol Malig Rep. 2015; 10(2):158-66. PMC: 4447524. DOI: 10.1007/s11899-015-0248-3. View

12.

Loscocco F, Visani G, Galimberti S, Curti A, Isidori A . BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia. Front Oncol. 2019; 9:939. PMC: 6769066. DOI: 10.3389/fonc.2019.00939. View

13.

Hosseinkhani N, Derakhshani A, Shadbad M, Argentiero A, Racanelli V, Kazemi T . The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Front Immunol. 2021; 12:676181. PMC: 8172140. DOI: 10.3389/fimmu.2021.676181. View

14.

Pagliuca S, Gurnari C, Zhang K, Kewan T, Bahaj W, Mori M . Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value. Int J Mol Sci. 2022; 23(23). PMC: 9735915. DOI: 10.3390/ijms232314885. View

15.

Chorzalska A, Ahsan N, Rao R, Roder K, Yu X, Morgan J . Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia. Mol Oncol. 2018; 12(5):630-647. PMC: 5928369. DOI: 10.1002/1878-0261.12186. View

16.

Sundaram D, Jiang X, Brandwein J, Valencia-Serna J, Remant K, Uludag H . Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. Drug Discov Today. 2019; 24(7):1355-1369. DOI: 10.1016/j.drudis.2019.05.007. View

17.

Stuckey R, Lopez Rodriguez J, Gomez-Casares M . Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission. Curr Oncol Rep. 2022; 24(4):415-426. PMC: 8930955. DOI: 10.1007/s11912-022-01228-w. View

18.

Chen Y, Xie X, Wu A, Wang L, Hu Y, Zhang H . A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. J Exp Clin Cancer Res. 2018; 37(1):12. PMC: 5778704. DOI: 10.1186/s13046-018-0682-x. View

19.

Chen Y, Feng R, He B, Wang J, Xian N, Huang G . PD-1H Expression Associated With CD68 Macrophage Marker Confers an Immune-Activated Microenvironment and Favorable Overall Survival in Human Esophageal Squamous Cell Carcinoma. Front Mol Biosci. 2021; 8:777370. PMC: 8688962. DOI: 10.3389/fmolb.2021.777370. View

20.

De Novellis D, Cacace F, Caprioli V, Wierda W, Mahadeo K, Tambaro F . The TKI Era in Chronic Leukemias. Pharmaceutics. 2021; 13(12). PMC: 8709313. DOI: 10.3390/pharmaceutics13122201. View